Obesity Clinical Trials

• Age ≥ 18 years.

• Body Mass index (BMI) ≥ 27 kg/m\^2 to ≤ 40 kg/m\^2 at screening.

• For participants with type 2 diabetes mellitus (T2DM) at screening:

• HbA1c ≤ 9.5% (80 mmol/mol) at screening.

• Treated with diet and exercise alone and/or a stable treatment with metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or combination.

• Liver Controlled Attenuation Parameter (CAPTM) ≥ 300 dB/meter via FibroScan® assessment.

• Liver fat content ≥ 10% by MRI as determined by the central imaging vendor at screening.

• MRI assessment should only be performed after all other eligibility has been confirmed whenever possible.

• History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.